EA200970180A1 - Способ предсказания агрегации белков и конструирования ингибиторов агрегации - Google Patents

Способ предсказания агрегации белков и конструирования ингибиторов агрегации

Info

Publication number
EA200970180A1
EA200970180A1 EA200970180A EA200970180A EA200970180A1 EA 200970180 A1 EA200970180 A1 EA 200970180A1 EA 200970180 A EA200970180 A EA 200970180A EA 200970180 A EA200970180 A EA 200970180A EA 200970180 A1 EA200970180 A1 EA 200970180A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aggregation
peptide sequence
construction
methods
protein aggregation
Prior art date
Application number
EA200970180A
Other languages
English (en)
Other versions
EA016884B1 (ru
Inventor
Кай Й. Колхофф
Хесус Сурдо
Микеле Вендрусколо
Original Assignee
ЛОНЗА БАЙОЛОДЖИКС ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЛОНЗА БАЙОЛОДЖИКС ПиЭлСи filed Critical ЛОНЗА БАЙОЛОДЖИКС ПиЭлСи
Publication of EA200970180A1 publication Critical patent/EA200970180A1/ru
Publication of EA016884B1 publication Critical patent/EA016884B1/ru

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение относится к способам предсказания агрегации белков и конструирования ингибиторов агрегации. Один из таких способов предсказания потенциальных пептидных последовательностей, ингибирующих агрегацию белка, включает стадии: а) идентификации пептидной последовательности, образующей по меньшей мере часть области агрегации в белке-мишени; b) тестирования образования указанной пептидной последовательностью β-слоя; с) если на стадии b) достигнут положительный результат, извлечения соседних цепей слоя; d) идентификации остатков в цепях, расположенных рядом с указанной пептидной последовательностью, боковые цепи которых взаимодействуют с указанной пептидной последовательностью, т.е. тех остатков, которые образуют потенциальную пептидную последовательность, ингибирующую агрегацию белка. Также настоящее изобретение относится к способом конструирования соединений с применением остатков, идентифицированных в указанном выше способе; к соединениям, продуцируемым этими способами, и к компьютерным программам для осуществления указанных выше способов.
EA200970180A 2006-08-04 2007-07-24 Способ предсказания агрегации белков и конструирования ингибиторов агрегации EA016884B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (2)

Publication Number Publication Date
EA200970180A1 true EA200970180A1 (ru) 2009-08-28
EA016884B1 EA016884B1 (ru) 2012-08-30

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970180A EA016884B1 (ru) 2006-08-04 2007-07-24 Способ предсказания агрегации белков и конструирования ингибиторов агрегации

Country Status (12)

Country Link
US (1) US8290713B2 (ru)
EP (1) EP2047393A1 (ru)
JP (1) JP2009545756A (ru)
KR (1) KR20090047470A (ru)
CN (1) CN101501694B (ru)
AU (1) AU2007280282B2 (ru)
CA (1) CA2657847A1 (ru)
EA (1) EA016884B1 (ru)
HK (1) HK1131239A1 (ru)
IL (1) IL196551A (ru)
SG (1) SG173405A1 (ru)
WO (1) WO2008015384A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
AU2009236583B2 (en) 2008-04-17 2015-07-16 Declion Holdings Llc Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN107677830A (zh) * 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
CN102686609A (zh) * 2009-10-23 2012-09-19 加文医学研究所 修饰的可变域分子及其生产和使用方法
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
WO2016112142A1 (en) * 2015-01-06 2016-07-14 North Carolina State University Modeling ribosome dynamics to optimize heterologous protein production
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CA3029676A1 (en) * 2016-06-29 2018-01-04 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020079731A (ko) * 1999-11-05 2002-10-19 액소닉스, 인코포레이티드. 아밀로이드, 아밀로이드-유사 침착물, 또는 β-쉬이트가풍부한 그의 병리학적 전구체로의 비정상적 단백질 폴딩과관련된 질환의 치료에 있어서 생체내에서 사용하기에적합한 펩티드 동족체 및 유사체
EP1646375A2 (en) * 2003-06-23 2006-04-19 Neurochem (International) Limited Treatment of protein aggregation disorders
GB0325817D0 (en) * 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Also Published As

Publication number Publication date
US20100160602A1 (en) 2010-06-24
EP2047393A1 (en) 2009-04-15
KR20090047470A (ko) 2009-05-12
CN101501694B (zh) 2011-11-30
IL196551A (en) 2013-01-31
SG173405A1 (en) 2011-08-29
US8290713B2 (en) 2012-10-16
WO2008015384A8 (en) 2008-05-15
IL196551A0 (en) 2009-11-18
CN101501694A (zh) 2009-08-05
WO2008015384A1 (en) 2008-02-07
HK1131239A1 (en) 2010-01-15
CA2657847A1 (en) 2008-02-07
AU2007280282A1 (en) 2008-02-07
AU2007280282B2 (en) 2012-02-02
JP2009545756A (ja) 2009-12-24
EA016884B1 (ru) 2012-08-30

Similar Documents

Publication Publication Date Title
EA200970180A1 (ru) Способ предсказания агрегации белков и конструирования ингибиторов агрегации
ES2570334T3 (es) Remodelado superficial de proteínas
Brinkman et al. Venom proteome of the box jellyfish Chironex fleckeri
Niec et al. Lymphatics act as a signaling hub to regulate intestinal stem cell activity
McVeigh et al. Fasciola hepatica virulence-associated cysteine peptidases: a systems biology perspective
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
PE20121361A1 (es) Antagonistas de pcsk9
PE20141787A1 (es) Composiciones anti-cgrp y uso de las mismas
PE20150023A1 (es) Proteinas de union a antigeno st2
CL2013002161A1 (es) Metodo para tratar enfermedad o afección en el que la expresión o la actividad de la proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) ocasionan un impacto; anticuerpo o fragmento de unión al antígeno que se une específicamente a la proproteína convertasa subtilisina/kexina tipo 9 (pcsk9).
EA200601657A1 (ru) Определение области действия параметра графа зависимостей
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
DK2185937T3 (da) Fremgangsmåde til at bestemme sepsis hos mennesker
MX2009000914A (es) Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
EA201170762A1 (ru) Способы отбора устойчивых к протеазе полипептидов
AR108717A1 (es) Anticuerpos antifactor de la coagulación xi
WO2005109000A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
AR055649A1 (es) Metodo de mejora de la funcion cognitiva
EA201590719A1 (ru) Фоллистатин в лечении мышечной дистрофии дюшенна
Ali et al. Proteomic comparison of Hypnale hypnale (hump-nosed pit-viper) and Calloselasma rhodostoma (Malayan pit-viper) venoms
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
Zobel-Thropp et al. Comparative analyses of venoms from American and African Sicarius spiders that differ in sphingomyelinase D activity
JP2014503191A5 (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU